Healthcare provider profile · identity verified

Ryan Scott Nagy, MD

Internal Medicine · YOUNGSTOWN, OH · NPI 1366603516

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	147	21
Atorvastatin Calcium	Atorvastatin Calcium	143	28
Xarelto	Rivaroxaban	139	suppressed
Metoprolol Succinate	Metoprolol Succinate	138	44
Amlodipine Besylate	Amlodipine Besylate	133	33
Levothyroxine Sodium	Levothyroxine Sodium	111	18
Gabapentin	Gabapentin	102	23
Pantoprazole Sodium	Pantoprazole Sodium	95	30
Furosemide	Furosemide	86	33
Metoprolol Tartrate	Metoprolol Tartrate	84	20
Lisinopril	Lisinopril	63	13
Levetiracetam	Levetiracetam	60	11
Trazodone Hcl	Trazodone Hcl	53	11
Mirtazapine	Mirtazapine	52	suppressed
Divalproex Sodium	Divalproex Sodium	50	11
Latanoprost	Latanoprost	48	suppressed
Sertraline Hcl	Sertraline Hcl	47	suppressed
Simvastatin	Simvastatin	46	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	44	13
Baclofen	Baclofen	43	11
Bumetanide	Bumetanide	39	19
Prednisone	Prednisone	38	33
Rivastigmine	Rivastigmine Tartrate	38	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	34	suppressed
Pyridostigmine Bromide	Pyridostigmine Bromide	33	suppressed
Memantine Hcl	Memantine Hcl	32	suppressed
Potassium Chloride	Potassium Chloride	32	13
Metformin Hcl	Metformin Hcl	31	suppressed
Omeprazole	Omeprazole	31	suppressed
Restasis Multidose	Cyclosporine	31	suppressed
Buspirone Hcl	Buspirone Hcl	30	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Allopurinol	Allopurinol	29	suppressed
Atenolol	Atenolol	28	suppressed
Famotidine	Famotidine	28	suppressed
Spironolactone	Spironolactone	27	12
Amiodarone Hcl	Amiodarone Hcl	26	suppressed
Lamotrigine	Lamotrigine	26	suppressed
Olanzapine	Olanzapine	26	suppressed
Sucralfate	Sucralfate	26	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Finasteride	Finasteride	23	suppressed
Linzess	Linaclotide	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Topiramate	Topiramate	20	suppressed
Losartan Potassium	Losartan Potassium	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Montelukast Sodium	Montelukast Sodium	18	suppressed
Paliperidone Er	Paliperidone	18	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Fluticasone Propionate	Fluticasone Propionate	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Cefdinir	Cefdinir	16	16
Hydroxyzine Pamoate	Hydroxyzine Pamoate	16	suppressed
Novolog	Insulin Aspart	16	suppressed
Timolol Maleate	Timolol Maleate	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	14
Warfarin Sodium	Warfarin Sodium	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Memantine Hcl Er	Memantine Hcl	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Valsartan	Valsartan	14	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Oxcarbazepine	Oxcarbazepine	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Enulose	Lactulose	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Rivastigmine	Rivastigmine	12	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	11	11
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error